CD19 and cancer: Specifically, we have shown that these tandem CAR T-cells were able to lyse CD19+ and CD19- cancer cells in both repeated antigen stimulation assays (mimicking chronic stimulation) and in an aggressive in vivo B-ALL model where tandem CAR T-cells successfully negated cancer relapse after multiple re-challenges.